Učitavanje...
Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis
Fibrosis is an underlying cause of cirrhosis and hepatic failure resulting in end stage liver disease with limited pharmacological options. The beneficial effects of relaxin peptide treatment were demonstrated in clinically relevant animal models of liver fibrosis. However, the use of relaxin is pro...
Spremljeno u:
| Izdano u: | FASEB J |
|---|---|
| Glavni autori: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Federation of American Societies for Experimental Biology
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6988856/ https://ncbi.nlm.nih.gov/pubmed/31419161 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1096/fj.201901046R |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|